Patents Assigned to GEISTLICH PHARMA AG
  • Publication number: 20220023498
    Abstract: A method, material, and kit for promoting neutrophils and monocytes to localize at a chronic ulcer site, promoting formation of a multi-layered cell structure in the ulcer site, promoting conversion of monocytes to macrophages, promoting secretion of the patient's own growth factors, promoting tissue proliferation and cell migration, promoting production and cross-linking of collagen at the chronic ulcer site, promoting growth of endothelial cells, promoting angiogenesis that was stalled at the chronic ulcer site, promoting formation of a vascular network and granulation, promoting oxygenation of the chronic ulcer site, and reducing one or more of purulent drainage, erythema, pain, warming, tenderness, induration, and bleeding at the chronic ulcer site.
    Type: Application
    Filed: December 16, 2020
    Publication date: January 27, 2022
    Applicants: Geistlich Pharma AG, University of Southern California
    Inventors: Charles ZELEN, David G. ARMSTRONG, Paul GLAT, Jarrod KAUFMAN, Marco MEHR, Lothar SCHLOESSER, Mark SPILKER
  • Publication number: 20210163432
    Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.
    Type: Application
    Filed: January 15, 2021
    Publication date: June 3, 2021
    Applicant: GEISTLICH PHARMA AG
    Inventors: Rolf W. PFIRRMANN, Hanns Moehler, Thomas Mueller
  • Patent number: 10968190
    Abstract: Methods for producing compounds useful in reactions to produce oxathiazin-like compounds are disclosed including a process of adding sodium 2-bromoethanesulfonate to a solution of benzyl alcohol and sodium benzyloxide to for mixture, boiling the mixture to reflux four times, concentrating under vacuum until dry, boiling with ethyl alcohol, filtering the ethyl alcohol, and concentrating to dryness to obtain solid sodium 2-benzyletherethanesulfonate.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: April 6, 2021
    Assignee: GEISTLICH PHARMA AG
    Inventor: Rolf W. Pfirrmann
  • Patent number: 10960107
    Abstract: A collagen matrix, granulate blend, and process for making and using a collagen matrix or granulate blend including collagen and particles or granules of a biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and a closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a homogeneous coarse external surface comprising flat crystal platelets.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: March 30, 2021
    Assignee: Geistlich Pharma AG
    Inventors: Claudio Zihlmann, Michael Bufler
  • Patent number: 10918592
    Abstract: An injectable aqueous implant formulation, and processes for making and using the formulation, wherein the injectable aqueous implant formulation has been sterilized by gamma-ray or X-ray-irradiation and can be extruded through a tapering system and an 18 gauge (0.838 mm inner diameter) 25.4 mm long cannula with a force not exceeding 60 N, which comprises 25-45 w/w % of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 ?m as determined by sieving and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve, whereby the w/w ratio of nanocrystalline hydroxyapatite to collagen is from 1.8 to 4.5, which contains at least 0.05% (w/w) ascorbic acid.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: February 16, 2021
    Assignee: Geistlich Pharma AG
    Inventors: Daniel Suppiger, Paul Buxton, Nino Kurz
  • Patent number: 10869949
    Abstract: A method, material, and kit for promoting neutrophils and monocytes to localize at a chronic ulcer site, promoting formation of a multi-layered cell structure in the ulcer site, promoting conversion of monocytes to macrophages, promoting secretion of the patient's own growth factors, promoting tissue proliferation and cell migration, promoting production and cross-linking of collagen at the chronic ulcer site, promoting growth of endothelial cells, promoting angiogenesis that was stalled at the chronic ulcer site, promoting formation of a vascular network and granulation, promoting oxygenation of the chronic ulcer site, and reducing one or more of purulent drainage, erythema, pain, warming, tenderness, induration, and bleeding at the chronic ulcer site.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: December 22, 2020
    Assignees: Geistlich Pharma AG, University of Southern California
    Inventors: Charles Zelen, David Armstrong, Paul Glat, Jarrod Kaufman, Marco Mehr, Lothar Schloesser, Mark Spilker
  • Publication number: 20200390934
    Abstract: A collagen matrix, granulate blend, and process for making and using a collagen matrix or granulate blend including collagen and particles or granules of a biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and a closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a homogeneous coarse external surface comprising flat crystal platelets.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 17, 2020
    Applicant: GEISTLICH PHARMA AG
    Inventors: Claudio ZIHLMANN, Michael BUFLER
  • Publication number: 20200390939
    Abstract: Collagen matrix granulate blend, and process for making and using a collagen matrix or granulate blend including collagen and particles of a biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and having its total external surface covered by at least one closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP is transformed from the CAP on the external surface of the sintered CAP core has a non-homogeneous external surface comprising individual clusters of flat crystal platelets consisting of epitactically grown HAP nanocrystals and coarse areas between the individual clusters, whereby the percentage of the coarse areas between the individual clusters as measured by SEM is at least 20% of the total surface.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 17, 2020
    Applicant: GEISTLICH PHARMA AG
    Inventors: Claudio ZIHLMANN, Michael BUFLER
  • Publication number: 20200390690
    Abstract: An injectable aqueous implant formulation, and processes for making and using the formulation, wherein the injectable aqueous implant formulation has been sterilized by gamma-ray or X-ray-irradiation and can be extruded through a tapering system and an 18 gauge (0.838 mm inner diameter) 25.4 mm long cannula with a force not exceeding 60 N, which comprises 25-45 w/w % of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 ?m as determined by sieving and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve, whereby the w/w ratio of nanocrystalline hydroxyapatite to collagen is from 1.8 to 4.5, which contains at least 0.05% (w/w) ascorbic acid.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 17, 2020
    Applicant: GEISTLICH PHARMA AG
    Inventors: Daniel SUPPIGER, Paul BUXTON, Nino KURZ
  • Patent number: 10835640
    Abstract: The invention relates to resorbable crosslinked form stable membrane which comprises a composite layer of collagen material and inorganic ceramic particles containing 1.5 to 3.5 weight parts of inorganic ceramic for 1 weight part of collagen material, sandwiched between two layers of elastic pretensed collagen material (collagen material that has been stretched such as to be in the linear/elastic region of the stress-strain curve), the collagen material comprising 50-100% (w/w) collagen and 0-50% (w/w) elastin, and has shape and dimensions suitable for use in human tissue regeneration outside the oral cavity in rhinoplasty, postlateral spinal fusion or orbital reconstruction.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: November 17, 2020
    Assignee: Geistlich Pharma AG
    Inventors: Niklaus Stiefel, Sergej Stenzel, Raphael Kaufmann
  • Publication number: 20200345893
    Abstract: A dried implant composition for preparing an injectable aqueous implant formulation that is extrudable through a tapering system and a gauge 18 cannula, including a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 ?m and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve; an injectable aqueous implant formulation, wherein the injectable aqueous implant formulation is obtainable by hydration and homogeneous mixing; a process for preparing the injectable aqueous implant formulation; and a kit for preparing the injectable aqueous implant formulation.
    Type: Application
    Filed: June 29, 2020
    Publication date: November 5, 2020
    Applicant: GEISTLICH PHARMA AG
    Inventors: Daniel SUPPIGER, Paul BUXTON, Nino KURZ
  • Publication number: 20200324020
    Abstract: A method, material, and kit for promoting neutrophils and monocytes to localize at a chronic ulcer site, promoting formation of a multi-layered cell structure in the ulcer site, promoting conversion of monocytes to macrophages, promoting secretion of the patient's own growth factors, promoting tissue proliferation and cell migration, promoting production and cross-linking of collagen at the chronic ulcer site, promoting growth of endothelial cells, promoting angiogenesis that was stalled at the chronic ulcer site, promoting formation of a vascular network and granulation, promoting oxygenation of the chronic ulcer site, and reducing one or more of purulent drainage, erythema, pain, warming, tenderness, induration, and bleeding at the chronic ulcer site.
    Type: Application
    Filed: April 10, 2020
    Publication date: October 15, 2020
    Applicants: Geistlich Pharma AG, University of Southern California
    Inventors: Charles ZELEN, David ARMSTRONG, Paul GLAT, Jarrod KAUFMAN, Marco MEHR, Lothar SCHLOESSER, Mark SPILKER
  • Patent number: 10736902
    Abstract: A method of treating a patient suffering from TNBC by a multidisciplinary method involving treating the patient with a plurality of the following treatments: i) one or more checkpoint inhibitors; ii) hyperthermia treatment; iii) low dose chemotherapy; iv) Interleukin-2 (IL-2); and v) a compound selected from the group consisting of taurolidine, taurultam, oxathiazin-like compounds, and combinations thereof.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: August 11, 2020
    Assignee: GEISTLICH PHARMA AG
    Inventors: H. Paul Redmond, Rolf W. Pfirrmann
  • Patent number: 10695461
    Abstract: A dried implant composition for preparing an injectable aqueous implant formulation that is extrudable through a tapering system and a gauge 18 cannula, including a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 ?m and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve; an injectable aqueous implant formulation for use in a method of oral tissue regeneration, wherein the injectable aqueous implant formulation is obtainable by hydration and homogeneous mixing; a process for preparing the injectable aqueous implant formulation; and a kit for preparing the injectable aqueous implant formulation for use in oral tissue regeneration.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: June 30, 2020
    Assignee: Geistlich Pharma AG
    Inventors: Daniel Suppiger, Paul Buxton, Nino Kurz
  • Patent number: 10646615
    Abstract: A biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and a closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a homogeneous coarse external surface comprising flat crystal platelets, which shows an enhanced osteogenic response, a method of promoting bone formation, bone regeneration and/or bone repair by implanting the biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material, and a process of preparation thereof.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: May 12, 2020
    Assignee: Geistlich Pharma AG
    Inventors: Claudio Zihlmann, Michael Bufler
  • Patent number: 10646619
    Abstract: A biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and at least one closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a non-homogeneous external surface comprising individual clusters of flat crystal platelets consisting of epitactically grown HAP nanocrystals and coarse areas between the individual clusters, whereby the percentage of the coarse areas between the individual clusters as measured by SEM is at least 20% of the total surface, which material shows an increased capacity to induce bone formation, and a process of preparation thereof.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: May 12, 2020
    Assignee: GEISTLICH PHARMA AG
    Inventors: Claudio Zihlmann, Michael Bufler
  • Patent number: 10544114
    Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes for efficient and safe manufacture of compounds useful for making oxathiazin-like compounds useful for treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: January 28, 2020
    Assignee: GEISTLICH PHARMA AG
    Inventor: Rolf W. Pfirrmann
  • Publication number: 20200016293
    Abstract: A biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and a closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a homogeneous coarse external surface comprising flat crystal platelets, which shows an enhanced osteogenic response, a method of promoting bone formation, bone regeneration and/or bone repair by implanting the biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material, and a process of preparation thereof.
    Type: Application
    Filed: September 25, 2019
    Publication date: January 16, 2020
    Applicant: GEISTLICH PHARMA AG
    Inventors: Claudio ZIHLMANN, Michael BUFLER
  • Publication number: 20190389819
    Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.
    Type: Application
    Filed: August 12, 2019
    Publication date: December 26, 2019
    Applicant: GEISTLICH PHARMA AG
    Inventor: Rolf W. PFIRRMANN
  • Patent number: 10392355
    Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: August 27, 2019
    Assignee: GEISTLICH PHARMA AG
    Inventor: Rolf W. Pfirrmann